Dyadic International Inc.
DYAI Healthcare Biotechnology
Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat, free cash flow fell 1,298.5% and total debt was flat, each against the same quarter a year earlier.
Follow DYAI
Dyadic International Inc. (DYAI) EV/Sales
As of 16 October 2026, Dyadic International Inc. (DYAI) trades at a EV/Sales of 4.0×. Over the past ten years it has ranged from −18.5× (April 2016) to 197× (December 2015); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.8× | (34.71%) |
| FY2024 | 13.5× | 0.95% |
| FY2023 | 13.3× | 47.34% |
| FY2022 | 9.0× | (79.41%) |
| FY2021 | 43.9× | (40.73%) |
| FY2020 | 74.1× | 17.90% |
| FY2019 | 62.9× | 633.31% |
| FY2018 | 8.6× | 3,309.23% |
| FY2017 | 0.3× | — |
| FY2016 | −8.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.7× | 17.11% |
| Mar 2026 | 7.4× | (15.18%) |
| Dec 2025 | 8.8× | (17.26%) |
| Sep 2025 | 10.6× | 55.48% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCRX TScan Therapeutics, Inc. compare | −5.3× |
| ATYR aTyr Pharma, Inc. compare | −3.4× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.3× |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| DYAI Dyadic International Inc. | 4.0× |
| ACGN Aceragen, Inc. compare | 4.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)